← Leaderboards
Marshall J Glesby
Weill Medical College Of Cornell Univ
$7,651,029
Attributed
$11,890,274
Total exposure
15
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2005–24$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$11,890,274 · 15
By mechanism
UH3$5,484,720 · 1
R01$1,775,985 · 1
UG3$1,432,888 · 1
R34$1,094,758 · 1
K24$891,879 · 1
M01$743,919 · 9
Top collaborators
- Robert J Kaner6 shared
- Monica L Guzman2 shared
Most similar at Weill Medical College Of Cornell Univ
Same institution · by research overlap
- Robert J Kaner$13,023,117
- Kristen M Marks$2,115,537
Others in their field
Top investigators on “Funding”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,479,940,681
- Leonard Freedman · Leidos Biomedical Research, Inc.$968,195,877
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Jeffrey P Krischer · University Of South Florida$358,470,093
Research focus
FundingResearch PersonnelDouble-Blind MethodRandomizedHiv InfectionsPilot ProjectsNatural HistoryDesignBaseChronicTrainingSafetyClinical TrialsHiv-1Antiretroviral TherapyClinical ResearchBloodResourcesGrantPatient Oriented ResearchGeneral PopulationRosiglitazonePlacebosPlasma
Grant awards (28)
1/2 Doxycycline for Emphysema in People Living with HIV: The DEPTH Trial$1,259,310
UH3 · FY2024 · HL
1/2 Doxycycline for Emphysema in People Living with HIV: The DEPTH Trial$2,092,028
UH3 · FY2023 · HL
1/2 Doxycycline for Emphysema in People Living with HIV: The DEPTH Trial$2,133,382
UH3 · FY2022 · HL
1/2 Doxycycline for Emphysema in People Living with HIV: The DEPTH Trial$1,432,888
UG3 · FY2021 · HL
Clonal Hematopoeisis in HIV and Aging$254,250
R21 · FY2021 · AG · contact PI
Clonal Hematopoeisis in HIV and Aging$211,875
R21 · FY2020 · AG · contact PI
Doxycycline for COPD in HIV-Infected Patients$520,748
R34 · FY2013 · HL
Doxycycline for COPD in HIV-Infected Patients$574,010
R34 · FY2012 · HL
Complications of Chronic Viral Infections$183,986
K24 · FY2012 · AI · contact PI
Complications of Chronic Viral Infections$182,478
K24 · FY2011 · AI · contact PI
Complications of Chronic Viral Infections$178,736
K24 · FY2010 · AI · contact PI
Complications of Chronic Viral Infections$175,103
K24 · FY2009 · AI · contact PI
Complications of Chronic Viral Infections$171,576
K24 · FY2008 · AI · contact PI
Growth Hormone and Rosiglitazone for Visceral Adoposity$251,356
R01 · FY2007 · DK · contact PI
STUDY OF SAFETY AND EFFICACY OF RHGH A/O ROSIGLITAZONE IN HIV$76,071
M01 · FY2007 · RR · contact PI
A5229 LIPOATROPHY STUDY$5,265
M01 · FY2007 · RR · contact PI
SUPPRESSIVE LONG-TERM ANTIVIRAL MANAGEMENT OF HCV AND HIV COINFECTED SUBJECTS$1,841
M01 · FY2007 · RR · contact PI
Growth Hormone and Rosiglitazone for Visceral Adoposity$455,184
R01 · FY2006 · DK · contact PI
STUDY OF SAFETY AND EFFICACY OF RHGH A/O ROSIGLITAZONE IN HIV$262,552
M01 · FY2006 · RR · contact PI
SUPPRESSIVE LONG-TERM ANTIVIRAL MANAGEMENT OF HCV AND HIV COINFECTED SUBJECTS$30,006
M01 · FY2006 · RR · contact PI
Growth Hormone and Rosiglitazone for Visceral Adoposity$492,881
R01 · FY2005 · DK
A5127: PH II TRIAL/ ADEFOVIR DIPIVOXIL/ TENOFOVIR DISOPROXIL FUMARATE/ HEP B/ H$57,199
M01 · FY2005 · RR
SUPPRESSIVE LONG-TERM ANTIVIRAL MANAGEMENT OF HCV AND HIV COINFECTED SUBJECTS$51,282
M01 · FY2005 · RR
A5163: PHASE II, STUDY OF ALENDRONATE IN HIV W/ DECREASED BMD$19,721
M01 · FY2005 · RR
GROWTH HORMONE AND ROSIGLITAZONE FOR HIV-ASSOCIATED LIPODYSTROPHY$13,804
M01 · FY2005 · RR
Growth Hormone and Rosiglitazone for Visceral Adiposity$576,564
R01 · FY2004 · DK
A5127: PH. II TRIAL/ ADEFOVIR DIPIVOXIL/ TENOFOVIR DISOPROXIL FUMARATE/ HEP B/ H$217,288
M01 · FY2004 · RR
A5163: PHASE II, STUDY OF ALENDRONATE IN HIV W/ DECREASED BMD$8,890
M01 · FY2004 · RR